{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T16:55:27Z","timestamp":1794070527792,"version":"4.8.0"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"16","license":[{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CDT-142654"],"award-info":[{"award-number":["CDT-142654"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Venous Thromboembolism Research Network","id":[{"id":"https:\/\/ror.org\/05d3e5897","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Patients with cancer and venous thromboembolism (VTE) have a high risk of recurrent VTE and anticoagulant-related bleeding. This study aimed to identify prognostic factors for these complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was performed for randomized trials and cohort studies evaluating prognostic factors for recurrent VTE or anticoagulant-related bleeding in adult patients with cancer and VTE. Adjusted hazard ratios (aHRs) for factors were pooled using random-effects meta-analysis. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-three studies (n = 96 753) were included in the meta-analyses. Factors with high certainty of association with increased risk of recurrent VTE included a previous history of VTE [aHR 1.50 (95% CI 1.08\u20132.09)], Eastern Cooperative Oncology Group (ECOG) performance status &amp;gt;0 [1.81 (1.34\u20132.46)] or &amp;gt;1 [2.44 (1.55\u20133.84)], advanced cancer [1.38 (1.15\u20131.65)], and specific cancer sites including lung [1.78 (1.29\u20132.46)], hepatobiliary [2.37 (1.70\u20133.30)], pancreas [3.20 (2.06\u20134.96)], and genitourinary [1.38 (1.14\u20131.67)]. Conversely, recent surgery [aHR 0.56 (95% CI 0.40\u20130.76)] and breast cancer [0.43 (0.23\u20130.81)] had a high certainty of association with a decreased risk. Factors with a high certainty of association with an increased risk of anticoagulant-related bleeding included a history of bleeding [aHR 2.41 (95% CI 1.50\u20133.88)], ECOG performance status \u22652 [2.10 (1.48\u20132.99)], advanced cancer [1.60 (1.29\u20131.97)], and cancers of the brain [2.25 (1.64\u20133.09)], gastrointestinal system [1.74 (1.44\u20132.11)], genitourinary system [1.90 (1.48\u20132.45)], and prostate [1.72 (1.26\u20132.34)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prognostic factors identified in this meta-analysis should be considered as part of risk stratification frameworks for anticoagulation management in patients with cancer and VTE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf453","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:47:54Z","timestamp":1749714474000},"page":"1917-1929","source":"Crossref","is-referenced-by-count":19,"title":["Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7570-0755","authenticated-orcid":false,"given":"Faizan","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary , 3330 Hospital 83 Drive NW, Calgary, Alberta , T2N 4N1","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Tritschler","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]},{"name":"Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina E","family":"Marx","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Lanting","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]},{"name":"Department of Internal Medicine, Tergooi Hospital , Hilversum ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Rochwerg","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Health Research Methods, Evidence, and Impact, McMaster University , Hamilton, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Tran","sequence":"additional","affiliation":[{"name":"Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute , Ottawa, Ontario ,","place":["Canada"]},{"name":"Departments of Medicine and Surgery, Faculty of Medicine, University of Ottawa , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon M","family":"Fernando","sequence":"additional","affiliation":[{"name":"Department of Critical Care, Lakeridge Health , Oshawa, Ontario ,","place":["Canada"]},{"name":"Department of Critical Care Medicine, Queen\u2019s University , Kingston, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane L","family":"Lorenzetti","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Cumming School of Medicine and Health Sciences Library, University of Calgary , Calgary, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Wunsch","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Weill Cornell Medical College , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessalyn","family":"Holodinsky","sequence":"additional","affiliation":[{"name":"Departments of Emergency Medicine, Community Health Sciences, and Clinical Neurosciences, Centre for Health Informatics, O'Brien Institute for Public Health, Hotchkiss Brain Institute, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary , Calgary, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Fiest","sequence":"additional","affiliation":[{"name":"Departments of Critical Care Medicine and Community Health Sciences, O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary , Calgary, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Thomas","family":"Stelfox","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Delluc","sequence":"additional","affiliation":[{"name":"Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute , Ottawa, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, University of Ottawa , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean A","family":"Fergusson","sequence":"additional","affiliation":[{"name":"Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Le Gal","sequence":"additional","affiliation":[{"name":"Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute , Ottawa, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, University of Ottawa , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S","family":"Wells","sequence":"additional","affiliation":[{"name":"Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute , Ottawa, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, University of Ottawa , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute , Ottawa, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, University of Ottawa , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Sanfilippo","sequence":"additional","affiliation":[{"name":"Department of Medicine, St. Louis Veterans Administration Medical Center, Washington University School of Medicine , St. Louis, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5256-6346","authenticated-orcid":false,"given":"Nick","family":"van Es","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Schrag","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M","family":"Connors","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-2972","authenticated-orcid":false,"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[{"name":"Inflammation and Chronic Disease Program, Ottawa Hospital Research Institute , Ottawa, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, University of Ottawa , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,22]]},"reference":[{"key":"2026042119590627400_ehaf453-B1","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1093\/eurheartj\/ehab171","article-title":"Relative risk of arterial and venous thromboembolism in persons with cancer vs persons without cancer\u2014a nationwide analysis","volume":"42","author":"Grilz","year":"2021","journal-title":"Eur Heart J"},{"key":"2026042119590627400_ehaf453-B2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1055\/a-2418-3960","article-title":"Risk of recurrent venous thromboembolism in patients with cancer: an individual patient data meta-analysis and development of a prediction model","volume":"125","author":"Lanting","year":"2025","journal-title":"Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B3","doi-asserted-by":"publisher","first-page":"102194","DOI":"10.1016\/j.eclinm.2023.102194","article-title":"The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis","volume":"64","author":"van Hylckama Vlieg","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026042119590627400_ehaf453-B4","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1182\/blood.2024025362","article-title":"Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study","volume":"144","author":"Englisch","year":"2024","journal-title":"Blood"},{"key":"2026042119590627400_ehaf453-B5","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1182\/bloodadvances.2022009577","article-title":"Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study","volume":"7","author":"Crobach","year":"2023","journal-title":"Blood Adv"},{"key":"2026042119590627400_ehaf453-B6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jval.2017.09.015","article-title":"What impact does venous thromboembolism and bleeding have on cancer patients\u2019 quality of life?","volume":"21","author":"Lloyd","year":"2018","journal-title":"Value Health"},{"key":"2026042119590627400_ehaf453-B7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/PPA.S79373","article-title":"Patients\u2019 experiences of living with cancer-associated thrombosis: the PELICAN study","volume":"9","author":"Noble","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"2026042119590627400_ehaf453-B8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"2026042119590627400_ehaf453-B9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026042119590627400_ehaf453-B10","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026042119590627400_ehaf453-B11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1161\/CIRCULATIONAHA.111.051920","article-title":"Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism","volume":"126","author":"Louzada","year":"2012","journal-title":"Circulation"},{"key":"2026042119590627400_ehaf453-B12","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.3324\/haematol.2019.222828","article-title":"Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"105","author":"Delluc","year":"2019","journal-title":"Haematologica"},{"key":"2026042119590627400_ehaf453-B13","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1160\/TH17-02-0116","article-title":"Low discriminating power of the modified Ottawa VTE risk score in a cohort of patients with cancer from the RIETE registry","volume":"117","author":"Alatri","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B14","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00520-013-1792-9","article-title":"Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score","volume":"21","author":"Ahn","year":"2013","journal-title":"Support Care Cancer"},{"key":"2026042119590627400_ehaf453-B15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1055\/s-0041-1735251","article-title":"Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score","volume":"122","author":"de Winter","year":"2022","journal-title":"Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1055\/a-2145-7238","article-title":"A novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer","volume":"124","author":"Cohen","year":"2024","journal-title":"Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B17","doi-asserted-by":"publisher","first-page":"e5595","DOI":"10.1136\/bmj.e5595","article-title":"Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes","volume":"346","author":"Hemmingway","year":"2013","journal-title":"BMJ"},{"key":"2026042119590627400_ehaf453-B18","doi-asserted-by":"publisher","first-page":"e1001380","DOI":"10.1371\/journal.pmed.1001380","article-title":"Prognosis research strategy (PROGRESS) 2: prognostic factor research","volume":"10","author":"Riley","year":"2013","journal-title":"PLoS Med"},{"key":"2026042119590627400_ehaf453-B19","doi-asserted-by":"publisher","first-page":"k4597","DOI":"10.1136\/bmj.k4597","article-title":"A guide to systematic review and meta-analysis of prognostic factor studies","volume":"364","author":"Riley","year":"2019","journal-title":"BMJ"},{"key":"2026042119590627400_ehaf453-B20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026042119590627400_ehaf453-B21","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B23","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B24","doi-asserted-by":"publisher","first-page":"e1001744","DOI":"10.1371\/journal.pmed.1001744","article-title":"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist","volume":"11","author":"Moons","year":"2014","journal-title":"PLoS Med"},{"key":"2026042119590627400_ehaf453-B25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"2026042119590627400_ehaf453-B26","doi-asserted-by":"publisher","first-page":"h870","DOI":"10.1136\/bmj.h870","article-title":"Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients","volume":"350","author":"Iorio","year":"2015","journal-title":"BMJ"},{"key":"2026042119590627400_ehaf453-B27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"J Clin Epi"},{"key":"2026042119590627400_ehaf453-B28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2026042119590627400_ehaf453-B29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"2026042119590627400_ehaf453-B30","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1200\/JCO.2010.34.0984","article-title":"Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients","volume":"29","author":"den Exter","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026042119590627400_ehaf453-B31","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.thromres.2013.01.025","article-title":"The incidence, risk factors, and prognosis of recurrent venous thromboembolism (VTE) in patients with advanced solid cancers receiving anticoagulation therapy after the diagnosis of index VTE","volume":"131","author":"Yhim","year":"2013","journal-title":"Thromb Res"},{"key":"2026042119590627400_ehaf453-B32","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1182\/blood-2014-01-549733","article-title":"Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study","volume":"123","author":"Chee","year":"2014","journal-title":"Blood"},{"key":"2026042119590627400_ehaf453-B33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1160\/TH16-09-0680","article-title":"Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours","volume":"117","author":"Chai-Adisaksopha","year":"2017","journal-title":"Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B34","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1111\/jth.13761","article-title":"Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study","volume":"15","author":"Dentali","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B35","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1200\/JCO.2016.67.4564","article-title":"Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: biomarker analyses of the CATCH trial","volume":"35","author":"Khorana","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026042119590627400_ehaf453-B36","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/jth.13664","article-title":"Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study","volume":"15","author":"Galanaud","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.amjmed.2016.10.017","article-title":"The clinical course of venous thromboembolism may differ according to cancer site","volume":"130","author":"Mah\u00e9","year":"2017","journal-title":"Am J Med"},{"key":"2026042119590627400_ehaf453-B38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.thromres.2017.05.019","article-title":"Recurrence of venous thromboembolism among adults acute leukemia patients treated at the University of Texas MD Anderson Cancer Center: Incidence and risk factors","volume":"156","author":"Luong","year":"2017","journal-title":"Thromb Res"},{"key":"2026042119590627400_ehaf453-B39","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/jth.14007","article-title":"Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study","volume":"16","author":"Kamphuisen","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B40","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"2026042119590627400_ehaf453-B41","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026042119590627400_ehaf453-B42","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/s41416-018-0269-5","article-title":"D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis","volume":"119","author":"Jara-Palomares","year":"2018","journal-title":"Br J Cancer"},{"key":"2026042119590627400_ehaf453-B43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.thromres.2018.01.009","article-title":"Predicting the risk of recurrent venous thromboembolism in patients with cancer: a prospective cohort study","volume":"163","author":"van Es","year":"2018","journal-title":"Thromb Res"},{"key":"2026042119590627400_ehaf453-B44","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/jth.14700","article-title":"Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: the Cleveland clinic experience","volume":"18","author":"Poudel","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.thromres.2020.02.005","article-title":"Patient characteristics and long\u2013term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism","volume":"188","author":"Schmidt","year":"2020","journal-title":"Thromb Res"},{"key":"2026042119590627400_ehaf453-B46","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1253\/circj.CJ-20-0084","article-title":"Direct oral anticoagulant therapy for cancer-associated venous thromboembolism in routine clinical practice","volume":"84","author":"Ogino","year":"2020","journal-title":"Circ J"},{"key":"2026042119590627400_ehaf453-B47","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1253\/circj.CJ-20-0223","article-title":"Risk factors for major bleeding during anticoagulation therapy in cancer-associated venous thromboembolism\u2015from the COMMAND VTE registry\u2015","volume":"84","author":"Nishimoto","year":"2020","journal-title":"Circ J"},{"key":"2026042119590627400_ehaf453-B48","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.3802\/jgo.2020.31.e10","article-title":"Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers","volume":"31","author":"Lee","year":"2020","journal-title":"J Gynecol Oncol"},{"key":"2026042119590627400_ehaf453-B49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1055\/a-1486-7497","article-title":"Failure of the Ottawa Score to predict the risk of recurrent venous thromboembolism in cancer patients: the prospective PREDICARE cohort study","volume":"122","author":"Girard","year":"2022","journal-title":"Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejim.2021.03.014","article-title":"Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE","volume":"88","author":"Giustozzi","year":"2021","journal-title":"Eur J Intern Med"},{"key":"2026042119590627400_ehaf453-B51","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejim.2021.05.029","article-title":"Risk factors of recurrence in patients with cancer-associated venous thromboembolism","volume":"91","author":"Nishimoto","year":"2021","journal-title":"Eur J Intern Med"},{"key":"2026042119590627400_ehaf453-B52","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.3390\/cancers14112771","article-title":"Biomarkers of venous thromboembolism recurrence after discontinuation of low molecular weight heparin treatment for cancer-associated thrombosis (HISPALIS-Study)","volume":"14","author":"Otero","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026042119590627400_ehaf453-B53","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.3390\/jcm11133729","article-title":"The Ottawa score performs poorly to identify cancer patients at high risk of recurrent venous thromboembolism: insights from the TROPIQUE study and updated meta-analysis","volume":"11","author":"Frere","year":"2022","journal-title":"J Clin Med"},{"key":"2026042119590627400_ehaf453-B54","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1055\/a-1777-4006","article-title":"Outcome of cancer-associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors","volume":"122","author":"Lecumberri","year":"2022","journal-title":"Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B55","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/j.jtha.2023.04.010","article-title":"Predictors of recurrence of cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a multicenter cohort study","volume":"21","author":"Lap\u00e9bie","year":"2023","journal-title":"J Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejim.2023.02.003","article-title":"Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism","volume":"112","author":"Vedovati","year":"2023","journal-title":"Eur J Intern Med"},{"key":"2026042119590627400_ehaf453-B57","doi-asserted-by":"publisher","first-page":"131271","DOI":"10.1016\/j.ijcard.2023.131271","article-title":"Risk of recurrent cancer-associated venous thromboembolism: a Danish nationwide cohort study","volume":"390","author":"Ording","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026042119590627400_ehaf453-B58","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1182\/blood-2023-191029","article-title":"Risk factors associated with anticoagulant-related bleeding in patients with cancer-associated thrombosis","volume":"142","author":"Loncharich","year":"2023","journal-title":"Blood"},{"key":"2026042119590627400_ehaf453-B59","doi-asserted-by":"publisher","first-page":"109184","DOI":"10.1016\/j.thromres.2024.109184","article-title":"Predictors of recurrent venous thromboembolism and major bleeding in patients with cancer: a secondary analysis of the CANVAS trial","volume":"244","author":"Uno","year":"2024","journal-title":"Thromb Res"},{"key":"2026042119590627400_ehaf453-B60","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1067\/mva.2003.191","article-title":"Factors associated with recurrent venous thromboembolism in patients with malignant disease","volume":"37","author":"Lin","year":"2003","journal-title":"J Vasc Surg"},{"key":"2026042119590627400_ehaf453-B61","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1160\/TH08-09-0563","article-title":"Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials","volume":"101","author":"van Doormaal","year":"2009","journal-title":"Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B62","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.thromres.2015.11.027","article-title":"Recurrent venous thromboembolism in glioblastoma","volume":"137","author":"Edwin","year":"2016","journal-title":"Thromb Res"},{"key":"2026042119590627400_ehaf453-B63","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1136\/ijgc-2019-000284","article-title":"Patients\u2019 experience and compliance with extended low molecular weight heparin prophylaxis post-surgery for gynecological cancer: a prospective observational study","volume":"29","author":"Marchocki","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"2026042119590627400_ehaf453-B64","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1055\/s-0040-1718728","article-title":"Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a US claims data analysis","volume":"121","author":"Cohen","year":"2021","journal-title":"Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B65","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1182\/bloodadvances.2020003136","article-title":"Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients","volume":"5","author":"Yan","year":"2021","journal-title":"Blood Adv"},{"key":"2026042119590627400_ehaf453-B66","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1055\/s-0042-1758835","article-title":"Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment","volume":"123","author":"McBane","year":"2023","journal-title":"Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B67","doi-asserted-by":"publisher","first-page":"100115","DOI":"10.1016\/j.rpth.2023.100115","article-title":"Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy","volume":"7","author":"Barca-Hernando","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B68","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12959-023-00502-6","article-title":"Prognosis of incidental pulmonary embolism vs symptomatic pulmonary embolism in cancer patients: a single-center retrospective cohort study in China","volume":"21","author":"Wang","year":"2023","journal-title":"Thromb J"},{"key":"2026042119590627400_ehaf453-B69","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"key":"2026042119590627400_ehaf453-B70","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"2026042119590627400_ehaf453-B71","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"2026042119590627400_ehaf453-B72","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"key":"2026042119590627400_ehaf453-B73","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/eurheartj\/ehac776","article-title":"Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score","volume":"44","author":"de Winter","year":"2023","journal-title":"Eur Heart J"},{"key":"2026042119590627400_ehaf453-B74","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jaccao.2023.10.009","article-title":"Comparing anticoagulation strategies for venous thromboembolism associated with active cancer: a systematic review and meta-analysis","volume":"6","author":"Fujisaki","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026042119590627400_ehaf453-B75","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jth.15599","article-title":"Extended anticoagulation treatment for cancer-associated thrombosis\u2014rates of recurrence and bleeding beyond 6 months: a systematic review","volume":"20","author":"Moik","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2026042119590627400_ehaf453-B76","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"Mulder","year":"2020","journal-title":"Blood"},{"key":"2026042119590627400_ehaf453-B77","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/16\/1917\/63538180\/ehaf453.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/16\/1917\/63538180\/ehaf453.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:59:15Z","timestamp":1776815955000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/16\/1917\/8170116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,22]]},"references-count":77,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,6,22]]},"published-print":{"date-parts":[[2026,4,22]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf453","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,21]]},"published":{"date-parts":[[2025,6,22]]}}}